Oragenics (OGEN) vs Purple Biotech (PPBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Purple Biotech is the larger company by market cap ($2.3 million vs $2.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGEN | PPBT |
|---|---|---|
| Share price | $0.463 | $1.44 |
| Market cap | $2.09M | $2.34M |
| 1-day change | -7.38% | -1.37% |
| EPS (TTM) | $-2.63 | $-47.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $14.10 |
| 52-week low | $0.46 | $1.16 |
| Distance from 52-week high | -68.07% | -89.79% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1080.56% |
| Average volume | 29.43K | 1.28M |
| Shares outstanding | 4.51M | 1.63M |
| Employees | 3 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Healthcare · Biotechnology · 3 employees
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Healthcare · Biotechnology · 10 employees
OGEN vs PPBT FAQ
Which is bigger, Oragenics or Purple Biotech?
Purple Biotech (PPBT) is larger, with a market capitalization of $2.34M compared with $2.09M for Oragenics (OGEN).
Are Oragenics and Purple Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.